We read with great interest the recent article by Leeds et al. (1) regarding the effect of the presence of celiac disease (CD) on glycometabolic parameters in type 1 diabetic subjects and, above all, on diabetes-related microvascular complications. Indeed, several epidemiological and genetic studies strongly suggest a more-than-random association between type 1 diabetes and CD (2,3), but no current guidelines encourage different approaches in patients with the coexistence of the two diseases in terms of glycometabolic targets and/or screening of vascular complications.We recently published a similar study (case-control) (4) that showed that the presence of CD is also associated with an increased intima-media thickness of the carotid arteries, a well-known intermediate marker of endothelial dysfunction and macrovascular disease. Therefore, although the intrinsic nature of the two studies does not allow for a definitive demonstration of a cause and effect relationship between CD and diabetes-related micro- and macrovascular complications, we strongly believe that:Type 1 diabeticpatients with an early presence of micro/macrovascular complications (in particular at the diagnosis) should be screened for CD; this is also true in the case of persistently high HbA1c values (“brittle diabetes”).The coexistence of CD and diabetes causes a worsening of metabolic control, above all if the former is not treated, which probably puts these patients in a higher-risk category. This is why it is reasonable to consider a more frequent screening for complications and to define different glycometabolic targets in this group of subjects. The consequence could be the application of different lowering-risk strategies, for example an early intervention with a statin and/or aspirin.We are well aware that these are, to date, just speculations. However, a growing body of evidence, including these two studies, suggests that we urgently need randomized controlled trials to explore these hypotheses.
Authors: D Pitocco; S Giubilato; F Martini; F Zaccardi; V Pazzano; A Manto; G Cammarota; E Di Stasio; D Pedicino; G Liuzzo; F Crea; G Ghirlanda Journal: Atherosclerosis Date: 2011-05-06 Impact factor: 5.162
Authors: Markku Mäki; Kirsi Mustalahti; Jorma Kokkonen; Petri Kulmala; Mila Haapalahti; Tuomo Karttunen; Jorma Ilonen; Kaija Laurila; Ingrid Dahlbom; Tony Hansson; Peter Höpfl; Mikael Knip Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245
Authors: John S Leeds; Andrew D Hopper; Marios Hadjivassiliou; Solomon Tesfaye; David S Sanders Journal: Diabetes Care Date: 2011-09-12 Impact factor: 19.112
Authors: Deborah J Smyth; Vincent Plagnol; Neil M Walker; Jason D Cooper; Kate Downes; Jennie H M Yang; Joanna M M Howson; Helen Stevens; Ross McManus; Cisca Wijmenga; Graham A Heap; Patrick C Dubois; David G Clayton; Karen A Hunt; David A van Heel; John A Todd Journal: N Engl J Med Date: 2008-12-10 Impact factor: 91.245